MA41505A - Nouvelle forme cristalline d'un inhibiteur de protéasome - Google Patents

Nouvelle forme cristalline d'un inhibiteur de protéasome

Info

Publication number
MA41505A
MA41505A MA041505A MA41505A MA41505A MA 41505 A MA41505 A MA 41505A MA 041505 A MA041505 A MA 041505A MA 41505 A MA41505 A MA 41505A MA 41505 A MA41505 A MA 41505A
Authority
MA
Morocco
Prior art keywords
crystalline form
proteasome inhibitor
new crystalline
new
proteasome
Prior art date
Application number
MA041505A
Other languages
English (en)
Inventor
Patricia Andres
Eric Elliott
Marianne Langston
Debra Mazaik
Anton Peterson
Jing Teng
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA41505A publication Critical patent/MA41505A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/05—Cyclic compounds having at least one ring containing boron but no carbon in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA041505A 2015-02-11 2016-02-09 Nouvelle forme cristalline d'un inhibiteur de protéasome MA41505A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562114838P 2015-02-11 2015-02-11
US201562265762P 2015-12-10 2015-12-10

Publications (1)

Publication Number Publication Date
MA41505A true MA41505A (fr) 2017-12-19

Family

ID=56615676

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041505A MA41505A (fr) 2015-02-11 2016-02-09 Nouvelle forme cristalline d'un inhibiteur de protéasome

Country Status (7)

Country Link
US (1) US10072029B2 (fr)
EP (1) EP3256481A4 (fr)
JP (3) JP2018506544A (fr)
CN (1) CN107207540A (fr)
HK (1) HK1243420A1 (fr)
MA (1) MA41505A (fr)
WO (1) WO2016130724A1 (fr)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (fr) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Inhibiteurs de la rénine
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
CA2435146C (fr) * 2001-01-25 2011-03-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Formulation de composes d'acide boronique
EP1399468B1 (fr) 2001-05-30 2006-02-15 Novartis AG Derives d'acide 2-((n-(2-amino-3-(heteroaryl ou aryl)propionyl)-aminoacyl)-amino)-alkylboronique
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
WO2006008660A2 (fr) 2004-07-20 2006-01-26 Affinium Pharmaceuticals, Inc. Nouveaux polypeptides purifies derives de streptococcus pneumoniae
CN101247799B (zh) 2005-07-05 2013-03-27 塔夫茨大学信托人 成纤维细胞活化蛋白α的抑制剂
US7630605B2 (en) 2007-06-26 2009-12-08 Corning Cable Systems Llc Optical fiber assemblies having relatively low-levels of water-swellable powder and methods therefor
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
SI2318419T2 (sl) * 2008-06-17 2025-10-30 Takeda Pharmaceutical Company Limited Spojine boronat estra in njihovi farmacevtski sestavki
EP2624818B1 (fr) * 2010-10-05 2017-04-05 Fresenius Kabi USA, LLC Formulations de bortézomib stabilisées par de l'acide borique
WO2012177835A1 (fr) * 2011-06-22 2012-12-27 Cephalon, Inc. Inhibiteurs du protéasome et leurs méthodes de préparation, de purification et d'utilisation

Also Published As

Publication number Publication date
US20180044356A1 (en) 2018-02-15
EP3256481A1 (fr) 2017-12-20
WO2016130724A1 (fr) 2016-08-18
EP3256481A4 (fr) 2018-08-22
CN107207540A (zh) 2017-09-26
JP2023126407A (ja) 2023-09-07
HK1243420A1 (zh) 2018-07-13
JP2018506544A (ja) 2018-03-08
JP2021042226A (ja) 2021-03-18
US10072029B2 (en) 2018-09-11

Similar Documents

Publication Publication Date Title
MA46866A (fr) Une forme cristalline d'un inhibiteur de magl
MA42606A (fr) Sels d'un inhibiteur de lsd1
EP3963061A4 (fr) Nouvelle nucléase crispr omni-50
DK3472157T3 (da) Krystallinske faste former af en bet-inhibitor
MA41252A (fr) Formes solides d'un inhibiteur d'ask 1
EP3365344A4 (fr) Sel d'un inhibiteur d'egfr, forme cristalline correspondante et utilisations correspondantes
EP2990057A4 (fr) Nouvelle application d'inhibiteur de pai-1
SG10201913200XA (en) Crystalline form of lorlatinib free base
EP3337485A4 (fr) Formes cristallines d'ibrutinib
EP3710546A4 (fr) Nouvelle composition caustique synthétique
EP3390422A4 (fr) Formes cristallines de lnt
IL269695A (en) Compounds useful as inhibitors of alcat 1
MA43580A (fr) L-valinate d'un dérivé d'hydroxypropylthiazolidine carboxamide, sel et forme cristalline polymorphe correspondants
EP2970290A4 (fr) Forme cristalline d'un composé anxiolytique
MA48944A (fr) Forme cristalline de n-butyldéoxygalactonojirimycine
EP3482750A4 (fr) Nouvelle utilisation d'un dérivé de sesquiterpène
EP3380482A4 (fr) Formes cristallines d'un composé de thiénopyrimidine
HUE047748T2 (hu) Eljárás aminotiolészter vegyületek és sóik elõállítására
BR112018003067A2 (pt) Processo para a síntese de uma lactama
EP2900240A4 (fr) Forme cristalline d'inhibiteur de transcriptase inverse
EP3511317A4 (fr) Nouvelle forme cristalline de sel de sodium de sacubitril
EP3395819A4 (fr) Forme cristalline de dérivé aminopyrane substitué
EP3692050A4 (fr) Nouvelle forme cristalline de 17-
ITUB20169994A1 (it) Nuove forme cristalline di farmaci immunomodulatori
EP3313667A4 (fr) Initiation d'un modèle de pénurie